PMID- 29779188 OWN - NLM STAT- MEDLINE DCOM- 20180723 LR - 20181114 IS - 1435-702X (Electronic) IS - 0721-832X (Print) IS - 0721-832X (Linking) VI - 256 IP - 8 DP - 2018 Aug TI - Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy. PG - 1411-1418 LID - 10.1007/s00417-018-4009-6 [doi] AB - PURPOSE: To determine whether the presence of vitreomacular interface abnormalities (VMIA) in patients with diabetic macular oedema (DMO) modifies the response to ranibizumab. METHODS: Medical records and spectral-domain optical coherence tomography (SD-OCT) scans of consecutive patients with centre-involving DMO initiating therapy with ranibizumab between December 2013 and March 2014 at the Belfast Health and Social Care Trust were reviewed. Patients were identified through an electronic database. Demographics; systemic baseline characteristics; history of previous ocular surgery/laser; best-corrected visual acuity (BCVA), central retinal thickness (CRT) and stage of retinopathy at presentation; and BCVA, CRT and presence/absence of fluid at the last follow-up were recorded. OCT scans were reviewed by a masked investigator who graded them for the presence/absence of VMIA at baseline and during follow-up and for the change in the posterior hyaloid face during follow-up. The association between (1) VMIA at baseline and (2) the change in the posterior hyaloid face during the follow-up and functional/anatomical outcomes was evaluated. RESULTS: One hundred forty-six eyes of 100 patients (mean age 63.5 years) followed for a mean of 9 months (range 2-14 months; only 9/146 dropped to follow-up before month 6) were included. Statistically significant differences were observed at baseline in BCVA (p = 0.007), previous macular laser and panretinal photocoagulation (PRP) (p = 0.006) and previous cataract surgery (p = 0.01) between eyes with and without VMIA, with better levels of vision, higher frequency of macular laser and lower frequency of PRP in eyes where no VMIA was present. Multivariable regression analysis did not disclose any statistically significant associations between VMIA at baseline or change in the posterior hyaloid face during the follow-up and functional and anatomical outcomes following treatment. CONCLUSION: VMIA are associated with worse presenting vision in patients with DMO; VMIA or change in the posterior hyaloid face during the follow-up did not modify the response to ranibizumab in this study. FAU - Mikhail, Michael AU - Mikhail M AD - Department of Ophthalmology, Belfast Health and Social Care Trust, Belfast, UK. FAU - Stewart, Stephen AU - Stewart S AD - Department of Ophthalmology, Belfast Health and Social Care Trust, Belfast, UK. FAU - Seow, Felicia AU - Seow F AD - Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, Belfast, UK. FAU - Hogg, Ruth AU - Hogg R AD - Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, Belfast, UK. FAU - Lois, Noemi AU - Lois N AD - Department of Ophthalmology, Belfast Health and Social Care Trust, Belfast, UK. n.lois@qub.ac.uk. AD - Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, Belfast, UK. n.lois@qub.ac.uk. LA - eng PT - Journal Article DEP - 20180519 PL - Germany TA - Graefes Arch Clin Exp Ophthalmol JT - Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie JID - 8205248 RN - 0 (Angiogenesis Inhibitors) RN - 2S9ZZM9Q9V (Bevacizumab) RN - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor) RN - ZL1R02VT79 (Ranibizumab) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Angiogenesis Inhibitors/administration & dosage MH - Bevacizumab/*administration & dosage MH - Diabetic Retinopathy/complications/diagnosis/*drug therapy MH - Female MH - Follow-Up Studies MH - Humans MH - Intravitreal Injections MH - Macula Lutea/drug effects/*pathology MH - Macular Edema/diagnosis/*drug therapy/etiology MH - Male MH - Middle Aged MH - Ranibizumab/*administration & dosage MH - Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors MH - Tomography, Optical Coherence/methods MH - *Visual Acuity MH - Vitreous Body/drug effects/*pathology MH - Young Adult PMC - PMC6060772 OTO - NOTNLM OT - Diabetic macular oedema OT - Intravitreal anti-VEGF injection OT - OCT imaging OT - Retina OT - Vitreomacular interface abnormalities COIS- CONFLICT OF INTEREST: The authors declare that they have no conflict of interest. ETHICAL APPROVAL: This was part of an audit approved by the Belfast Health and Social Care Trust (4966); full ethical review was therefore waived. For this type of study, formal consent is not required. EDAT- 2018/05/21 06:00 MHDA- 2018/07/24 06:00 PMCR- 2018/05/19 CRDT- 2018/05/21 06:00 PHST- 2018/02/20 00:00 [received] PHST- 2018/05/03 00:00 [accepted] PHST- 2018/04/30 00:00 [revised] PHST- 2018/05/21 06:00 [pubmed] PHST- 2018/07/24 06:00 [medline] PHST- 2018/05/21 06:00 [entrez] PHST- 2018/05/19 00:00 [pmc-release] AID - 10.1007/s00417-018-4009-6 [pii] AID - 4009 [pii] AID - 10.1007/s00417-018-4009-6 [doi] PST - ppublish SO - Graefes Arch Clin Exp Ophthalmol. 2018 Aug;256(8):1411-1418. doi: 10.1007/s00417-018-4009-6. Epub 2018 May 19.